Overview

GW786034 in Treating Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)